{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:45:36Z","timestamp":1790646336031,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.amjcard.2022.10.053","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:01:36Z","timestamp":1671494496000},"page":"S35-S42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S1","title":["Care of Patients With Transthyretin Amyloidosis: the Roles of Nutrition, Supplements, Exercise, and Mental Health"],"prefix":"10.1016","volume":"185","author":[{"given":"Noel R.","family":"Dasgupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2022.10.053_bib0001","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1146\/annurev-biochem-072611-130030","article-title":"Systemic amyloidoses","volume":"82","author":"Blancas-Mej\u00eda","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0002","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000506696","article-title":"The pathology of amyloidosis in classification: a review","volume":"143","author":"Picken","year":"2020","journal-title":"Acta Haematol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0004","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10741-014-9462-7","article-title":"Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs","volume":"20","author":"Casta\u00f1o","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0005","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","article-title":"Diagnosis, prognosis, and therapy of transthyretin amyloidosis","volume":"66","author":"Gertz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0006","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0007","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/mus.26515","article-title":"Burden of hereditary transthyretin amyloidosis on quality of life","volume":"60","author":"Yarlas","year":"2019","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0008","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/j.jacc.2019.01.072","article-title":"Exercise intolerance in patients with heart failure: JACC State-of-the-Art Review","volume":"73","author":"Del Buono","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0009","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13023-021-01706-7","article-title":"Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups","volume":"16","author":"Rintell","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0010","doi-asserted-by":"crossref","first-page":"e13354","DOI":"10.1111\/nmo.13354","article-title":"Abnormal small bowel motility in patients with hereditary transthyretin amyloidosis","volume":"30","author":"Wixner","year":"2018","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0011","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/nrgastro.2009.147","article-title":"Systemic amyloidosis and the gastrointestinal tract","volume":"6","author":"Sattianayagam","year":"2009","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2022.10.053_bib0012","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10286-019-00628-6","article-title":"Diagnosis and treatment of gastrointestinal dysfunction in hereditary TTR amyloidosis","volume":"29","author":"Obici","year":"2019","journal-title":"Clin Auton Res"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2982.2012.01991.x","article-title":"Gastric emptying in hereditary transthyretin amyloidosis: the impact of autonomic neuropathy","volume":"24","author":"Wixner","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0014","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.0954-6820.1983.tb08613.x","article-title":"Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms","volume":"214","author":"Steen","year":"1983","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0015","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1750-1172-9-61","article-title":"THAOS investigators. THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease","volume":"9","author":"Wixner","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506129.2019.1698417","article-title":"Markers of nutritional status and inflammation in transthyretin cardiac amyloidosis: association with outcomes and the clinical phenotype","volume":"27","author":"Driggin","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0017","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2796.1994.tb01106.x","article-title":"Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy","volume":"235","author":"Suhr","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0018","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/mus.25257","article-title":"Clinical measures in transthyretin familial amyloid polyneuropathy","volume":"55","author":"Coelho","year":"2017","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0019","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1007\/s00415-013-7051-7","article-title":"Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy","volume":"260","author":"Coelho","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0021","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0022","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0023","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s11886-015-0653-1","article-title":"Emerging advances in the management of cardiac amyloidosis","volume":"17","author":"Vranian","year":"2015","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0024","first-page":"1","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","author":"Adams","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40120-014-0023-8","article-title":"Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis","volume":"3","author":"Suhr","year":"2014","journal-title":"Neurol Ther"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0026","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/00325481.2017.1383819","article-title":"Modulation of the gut microbiota: a focus on treatments for irritable bowel syndrome","volume":"129","author":"Harris","year":"2017","journal-title":"Postgrad Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0027","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJM199004123221502","article-title":"Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies","volume":"322","author":"Janssens","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0028","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1055\/s-0032-1301754","article-title":"Medical management of constipation","volume":"25","author":"Portalatin","year":"2012","journal-title":"Clin Colon Rectal Surg"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0029","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrgastro.2016.53","article-title":"Diagnosis and management of chronic constipation in adults","volume":"13","author":"Rao","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0030","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/apt.12571","article-title":"Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation","volume":"39","author":"Shin","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0031","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.nmd.2016.03.006","article-title":"Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy","volume":"26","author":"Russo","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0032","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bcp.2017.04.004","article-title":"Natural product-based amyloid inhibitors","volume":"139","author":"Velander","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0033","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061287","article-title":"Uncovering the neuroprotective mechanisms of curcumin on transthyretin amyloidosis","volume":"20","author":"Ferreira","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0034","doi-asserted-by":"crossref","first-page":"e29933","DOI":"10.1371\/journal.pone.0029933","article-title":"Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: \"in vivo\" evidence from FAP mice models","volume":"7","author":"Ferreira","year":"2012","journal-title":"PLOS ONE"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0035","doi-asserted-by":"crossref","unstructured":"aus dem Siepen F, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV. Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther 2015;9:6319\u20136325.","DOI":"10.2147\/DDDT.S96893"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0036","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00392-010-0142-x","article-title":"Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis","volume":"99","author":"Mereles","year":"2010","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0037","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.pharmthera.2017.06.011","article-title":"Novel pharmacotherapies for cardiac amyloidosis","volume":"180","author":"Alexander","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0038","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.bbadis.2008.05.005","article-title":"Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of familial amyloidotic polyneuropathy","volume":"1782","author":"Macedo","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0039","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1479-5876-8-74","article-title":"Synergy of combined doxycycline\/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models","volume":"8","author":"Cardoso","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0040","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1096\/fj.05-4509com","article-title":"Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model","volume":"20","author":"Cardoso","year":"2006","journal-title":"FASEB J"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2022.10.053_bib0041","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/13506129.2012.678508","article-title":"Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study","volume":"19","author":"Obici","year":"2012","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0042","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.004969","article-title":"Chronotropic incompetence in chronic heart failure","volume":"11","author":"Zweerink","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.605282","article-title":"Clinical 3-D gait assessment of patients with polyneuropathy associated with hereditary transthyretin amyloidosis","volume":"11","author":"Vilas-Boas","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0044","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.1993.03510140062030","article-title":"Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators","volume":"270","author":"Bittner","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0045","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ejhf.2016","article-title":"Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis","volume":"23","author":"Nicol","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0046","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchf.2013.11.004","article-title":"Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction","volume":"2","author":"Mohammed","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0047","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Cardiac Amyloidosis: evolving diagnosis and management: a Scientific Statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0048","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13506129.2018.1496077","article-title":"Peak V'O 2 is an independent predictor of survival in patients with cardiac amyloidosis","volume":"25","author":"Hein","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0049","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCHEARTFAILURE.109.881326","article-title":"Six-minute walk test and cardiopulmonary exercise testing in patients with chronic heart failure: a comparative analysis on clinical and prognostic insights","volume":"2","author":"Guazzi","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0050","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1053\/euhj.2000.2310","article-title":"Six-minute walking performance in patients with moderate-to-severe heart failure; is it a useful indicator in clinical practice?","volume":"22","author":"Opasich","year":"2001","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0051","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1056\/NEJMoa1510774","article-title":"NHLBI Heart Failure Clinical Research Network. Isosorbide mononitrate in heart failure with preserved ejection fraction","volume":"373","author":"Redfield","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0052","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2022.10.053_bib0053","article-title":"Study Design and Rationale of Helios-B: A phase 3 study to evaluate the clinical efficacy and safety of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy","volume":"75","author":"Shilling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0054","unstructured":"Alnylam Pharmaceuticals. HELIOS-B: a study to evaluate vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. ClinicalTrials.gov identifier: NCT04153149 updated September 16, 2022. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04153149. Accessed on September 25, 2022."},{"key":"10.1016\/j.amjcard.2022.10.053_bib0055","unstructured":"Ionis Pharmaceuticals, Inc. CARDIO-TTRansform: a study to evaluate the efficacy and safety of eplontersen (formerly known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in participants with transthyretin-mediated amyloid cardiomyopathy (ATTR CM). ClinicalTrials.gov identifier: NCT04136171 updated September 2, 2022. Available at: https:\/\/ClinicalTrials.gov\/show\/NCT04136171. Accessed on September 25, 2022."},{"key":"10.1016\/j.amjcard.2022.10.053_bib0056","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0002-9149(97)82785-3","article-title":"Symptomatic conduction system disease in cardiac amyloidosis","volume":"80","author":"Mathew","year":"1997","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0057","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1161\/CIRCHEARTFAILURE.111.965186","article-title":"Modest increase in peak VO2 is related to better clinical outcomes in chronic heart failure patients: results from heart failure and a controlled trial to investigate outcomes of exercise training","volume":"5","author":"Swank","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0058","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/CIRCHEARTFAILURE.114.001825","article-title":"Mechanisms of exercise intolerance in heart failure with preserved ejection fraction: the role of abnormal peripheral oxygen extraction","volume":"8","author":"Dhakal","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0059","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/13506129.2018.1498782","article-title":"Seven factors predict a delayed diagnosis of cardiac amyloidosis","volume":"25","author":"Bishop","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0060","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40119-021-00219-5","article-title":"Impact of delayed diagnosis and misdiagnosis for patients with transthyretin amyloid cardiomyopathy (ATTR-CM): a targeted literature review","volume":"10","author":"Rozenbaum","year":"2021","journal-title":"Cardiol Ther"},{"issue":"suppl 1","key":"10.1016\/j.amjcard.2022.10.053_bib0061","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1750-1172-10-S1-P22","article-title":"Patient experience with hereditary and senile systemic amyloidoses: a survey from the Amyloidosis Research Consortium","volume":"10","author":"Lousada","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0062","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40120-018-0106-z","article-title":"Characterizing the high disease burden of transthyretin amyloidosis for patients and caregivers","volume":"7","author":"Stewart","year":"2018","journal-title":"Neurol Ther"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0063","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1212\/WNL.0000000000001870","article-title":"Rapid progression of familial amyloidotic polyneuropathy: a multinational natural history study","volume":"85","author":"Adams","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0064","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1080\/13506129.2018.1428795","article-title":"Psychopathological dimensions in subjects with hereditary ATTR V30M amyloidosis and their relation with life events due to the disease","volume":"25","author":"Lopes","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0065","first-page":"211","article-title":"Do canes or walkers make any difference? Nonuse and fall injuries","volume":"57","author":"Luz","year":"2017","journal-title":"Gerontologist"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0066","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0067","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1177\/2047487319884371","article-title":"Red flags in cardiac amyloidosis","volume":"27","author":"Kwok","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0068","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10741-015-9480-0","article-title":"Cardiac amyloidosis: the great pretender","volume":"20","author":"Rapezzi","year":"2015","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0069","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jchf.2019.04.010","article-title":"Screening for transthyretin amyloid cardiomyopathy in everyday practice","volume":"7","author":"Witteles","year":"2019","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.amjcard.2022.10.053_bib0070","doi-asserted-by":"crossref","DOI":"10.1177\/11795468211015230","article-title":"Best practices in specialized amyloidosis centers in the United States: a survey of cardiologists, nurses, patients, and patient advocates","volume":"15","author":"Nativi-Nicolau","year":"2021","journal-title":"Clin Med Insights Cardiol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914922011766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:07:40Z","timestamp":1762078060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914922011766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":70,"alternative-id":["S0002914922011766"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.053","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Care of Patients With Transthyretin Amyloidosis: the Roles of Nutrition, Supplements, Exercise, and Mental Health","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}